Page results
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
Dr Alegre Abarrategui is a consultant in diagnostic neuropathology offering diagnostic services across neuropathology subspecialties, especially surgical neuropathology, neuromuscular neuropathology, and neurodegeneration.
-
UCLH Charity is delighted to announce that the Dangoor Family’s Exilarch’s Foundation has pledged a £1.2m gift to support the next phase of the development of the CAR T programme at University College London Hospitals NHS Foundation Trust (UCLH). The CAR T Speed Release Project aims to reduce the time between extracting patient’s stem cells and injecting re-engineered CAR T cells back into patients with cancer to fight cancer cells.
-
Testing for NHS staff, provided by the Francis Crick Institute and UCLH NHS Foundation Trust, detected COVID-19 infections that would have otherwise been missed.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
This page is designed for parents/carers of children and young people who are scheduled to attend the paediatric audiology department. It outlines the various clinics your child may be seen in on the day of their appointment.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Cancer surgery at UCLH on Operation Ouch
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
File results
-
FOI/2024/0400 - Gestational Diabetes Mellitus (GDM) screening and fetal outcomes
-
FOI/2024/0381 - Proton Beam Therapy Centre material use, architectural technology and performance
-
FOI/2024/0385 - Immunoglobulin vials (by brands) distributed to patients
-
FOI/2024/0393 - Translation service/ communication spend
-
FOI/2024/0394 - Private maternity services 2012, 2016, 2018, 2022 and 2023
-
FOI/2024/0395 - Treatment and services for duchenne muscular dystrophy
-
FOI/2024/0403 - Risk Policy and corporate risk register
-
FOI/2024/0409 - Number of A&E attendees with mental health complaints from 2022 to 2024
-
FOI/2024/0406 - Staff and patient discrimination complaints in 2021, 2022 and 2023
-
FOI/2024/0635 - Patient incidences/ injuries due to chiropractic treatment